In a major effort to provide high quality affordable drugs to the cancer patients in the country, Biocon has now introduced Abraxane for breast cancer after failure of combination therapy. The drug, which is a paclitaxel protein-bound particles for injection suspension albumin-bound particles of approximately 130 nanometers is priced at $400 as against the current US price of $1,000 making it cheaper by 60 percent for scores of breast cancer patients.
The details can be read here.
No comments:
Post a Comment